A 12-page Executive Summary offering summary highlights for 22 Accountable Care Organizations and ACO solutions companies regarding their successes during the most recent MSSP performance year.
GoodRx: The 10 most expensive drugs approved in 2018
- Takhzyro — $573
- 820 (Hereditary angioedema*)
- Tegsedi — $449
- 800 (Hereditary polyneuropathy)
- Vitrakvi — $399
- 069 (Solid tumors)
- Tibsovo — $317
- 733 (Acute myeloid leukemia)
- Galafold — $315
- 250 (Fabry disease)
- Symdeko — $292
- 000 (Cystic fibrosis)
- Xospata — $273
- 750 (Acute myeloid leukemia
- Lobrena — $195
- 345 (Lung cancer)
- Palynziq — $178
- 120 (Phenylketonuria)
- Talzenna — $177
- 390 (Breast cancer)
ACO Performance Case Studies
*By signing up for this offer you agree to receive the Accountable Care bulletin and the HealthExecWire news release bulletin.
Accountable Care
Offerings
Value-Based Payments
Offerings
Analytics
Offerings
Population Health
Offerings
Payers & Providers
Offerings